

## DESCRIPTION


|                           |  |
|---------------------------|--|
| <b>Species Reactivity</b> | Human  |
| <b>Specificity</b>        | Stains human KIR2DL4 transfected BaF/3 cells. It does not recognize transfectants that express KIR2DL1, 2DL2, 2DL3, 2DL5, 2DS1, 2DS2, 2DS4, 3DL1, 3DL2, or 3DS1.   |
| <b>Source</b>             | Monoclonal Mouse IgG <sub>2A</sub> Clone # 181703  |
| <b>Purification</b>       | Protein A or G purified from hybridoma culture supernatant   |
| <b>Immunogen</b>          | BaF3 mouse pro-B cell line transfected with human KIR2DL4<br>Accession # Q99706  |
| <b>Conjugate</b>          | Phycoerythrin<br>Excitation Wavelength: 488 nm<br>Emission Wavelength: 565-605 nm  |
| <b>Formulation</b>        | Supplied in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details.<br><br>*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions. |

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

|                       | Recommended Concentration        | Sample    |
|-----------------------|----------------------------------|-----------|
| <b>Flow Cytometry</b> | 10 $\mu$ L/10 <sup>6</sup> cells | See Below |

## DATA



## PREPARATION AND STORAGE

|                                |  |
|--------------------------------|--|
| <b>Shipping</b>                | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.                                  |
| <b>Stability &amp; Storage</b> | <b>Protect from light. Do not freeze.</b> <ul style="list-style-type: none"> <li>12 months from date of receipt, 2 to 8 °C as supplied.</li> </ul> |

## BACKGROUND

KIR2DL4 (also known as 2DL4, p49, CD158d, KIR103) is a type I transmembrane protein of the killer cell Ig-like receptor (KIR) family expressed on NK and subsets of  $\gamma\delta$ T and memory/effector  $\alpha\beta$ T cells. KIR2DL4 is a unique KIR (1-3); alleles are not clonally restricted but are expressed codominantly (4) in all activated NK cells and constitutively on CD56<sup>hi</sup> NK cells. KIR members with two Ig-like domains (2D) usually express domains D1 and D2, but KIR2DL4 expresses D0 and D2. Other long-tailed (L) KIR have two cytoplasmic inhibitory signaling domains (ITIM), but KIR2DL4 has one ITIM and also exhibits characteristics of activating KIR (2). An arginine within the transmembrane sequence of KIR2DL4 interacts with the signaling molecule Fc $\epsilon$ R1- $\gamma$ , while in activating KIR, a transmembrane lysine interacts with DAP12 (1, 5). The KIR2DL4 gene is highly polymorphic. Seven splice variants missing one or more exons have been identified, but it is not clear whether these are expressed. Several of the nine alleles identified encode a frameshift creating a prematurely truncated protein. It is estimated that up to 25% of humans do not express KIR2DL4 capable of reaching the cell surface (1, 7, 10). Human KIR2DL4 is 65-83% amino acid identical to other primates. KIR receptors have no structural orthologs in non-primates, although mouse Ly49 proteins are functional orthologs. Cross-linking of KIR2DL4 induces NK cells to produce IFN- $\gamma$  (6, 7); stimulation with IL-2 upregulates cell surface expression on CD56<sup>dim</sup> cells and allows cytotoxicity (7). Although a role in immune privilege of the fetus has been suggested due to reported recognition of fetal trophoblast HLA-G by KIR2DL4 in the maternal decidua (11), subsequent data have not supported this recognition (1, 9).

## References:

1. Lanier, L.L. (2005) *Annu. Rev. Immunol.* **23**:225.
2. Faure, M. and E.O. Long (2002) *J. Immunol.* **168**:6208.
3. Selvakumar, A. *et al.* (1996) *Tissue Antigens* **48**:285.
4. Chan, H-W. *et al.* (2003) *J. Exp. Med.* **197**:245.
5. Kikuchi-Maki, A. *et al.* (2005) *J. Immunol.* **174**:3859.
6. Rajagopalan, S. *et al.* (2001) *J. Immunol.* **167**:1877.
7. Kikuchi-Maki, A. *et al.* (2003) *J. Immunol.* **171**:3415.
8. Gedil, M.A. *et al.* (2005) *Tissue Antigens* **65**:402.
9. Witt, C.S. *et al.* (2002) *Eur. J. Immunol.* **32**:18.
10. Goodridge, J.P. *et al.* (2003) *J. Immunol.* **171**:1768.
11. Ponte, M. *et al.* (1999) *Proc. Natl. Acad. Sci. USA* **96**:5674.